Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.5471
+0.0082 (1.52%)
At close: Mar 6, 2026, 4:00 PM EST
0.5200
-0.0271 (-4.95%)
After-hours: Mar 6, 2026, 7:59 PM EST
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $493.10K in the quarter ending September 30, 2025, a decrease of -85.58%. This brings the company's revenue in the last twelve months to $4.49M, up 1.51% year-over-year. In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth.
Revenue (ttm)
$4.49M
Revenue Growth
+1.51%
P/S Ratio
0.44
Revenue / Employee
$560,997
Employees
8
Market Cap
1.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | 2.17M | 122.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 60 Degrees Pharmaceuticals | 1.36M |
| Lyra Therapeutics | 600.00K |
| PMGC Holdings | 285.95K |
| Azitra | 7.50K |
| Virax Biolabs Group | 2.99K |
ENSC News
- 2 days ago - Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans - Accesswire
- 3 days ago - Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology - Accesswire
- 7 days ago - Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
- 9 days ago - Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Accesswire
- 11 days ago - Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Accesswire
- 5 weeks ago - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain - Accesswire
- 6 weeks ago - Ensysce Biosciences Expands Global Opioid Patent Portfolio - Accesswire
- 2 months ago - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Accesswire